Steven M. Horwitz, MD, on PTCL: Update on Efficacy of Duvelisib Dose Optimization

January 05, 2021 By The ASCO Post Staff

Steven M. Horwitz, MD, of Memorial Sloan Kettering Cancer Center, discusses phase II data from the Primo trial, which support continued evaluation of duvelisib as a treatment option for relapsed or refractory peripheral T-cell lymphoma due to consistent response rates (Abstract 44).

Related Content